Pacific Edge Limited
PEB.NZ
New Zealand Exchange0.29
NZD
+0.01
- -
Pacific Edge Limited
PEB.NZ
(New Zealand Exchange)
Recent
price
0.29
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Pacific Edge Limited (NZX: PEB), founded in 2001 and headquartered in Dunedin, New Zealand, specializes in the discovery, development, and commercialization of molecular diagnostic and prognostic tests for the early detection and management of bladder cancer; the company operates central laboratories in New Zealand and the United States, serving urologists and healthcare providers globally with non-invasive urine-based assays that utilize genetic and phenotypic biomarkers for superior accuracy over traditional cytology. Its core commercial portfolio comprises the Cxbladder suite of four proprietary tests—Cxbladder Detect, Triage, Monitor, and a suite addressing hematuria investigation, initial triage, post-treatment surveillance, and recurrence monitoring—validated through international multi-center clinical studies and included in the American Urological Association (AUA) guidelines for microhematuria evaluation; these products target unmet needs in urothelial cancer pathways, enabling faster clinical decisions, reduced cystoscopies, and improved patient outcomes in markets including North America, Europe, and Asia-Pacific. Pacific Edge segments its operations into Commercial (laboratory testing and sales worldwide) and Research (ongoing R&D in New Zealand and Australia), with approximately 114 employees supporting product innovation, regulatory compliance, and market access efforts. In recent developments, Pacific Edge launched a NZ$20 million capital raise in May 2025, comprising a NZ$15 million placement to institutional investors and a NZ$5 million share purchase plan for retail shareholders at NZ$0.10 per share, successfully securing NZ$16 million in the placement with oversubscriptions and closing the SPP with NZ$20.7 million total pledges by July 2025 to extend cash reserves beyond 12 months amid U.S. Medicare non-coverage for certain tests effective April 2025; proceeds fund accelerated Cxbladder Triage adoption leveraging AUA guideline inclusion, clinical evidence generation for enhanced Triage Plus and Monitor Plus variants, appeals for Medicare reconsideration, growth in non-Medicare U.S. channels, and development of in-vitro diagnostic (IVD) kits for decentralized international deployment. The company continues advancing its first-mover advantage in bladder cancer diagnostics, with directors and senior management participating in the equity raise and robust FY25 financials underscoring commercial momentum despite reimbursement challenges.